Identification of GDF15 peptide fragments inhibiting GFRAL receptor signaling

Peptides. 2023 Oct:168:171063. doi: 10.1016/j.peptides.2023.171063. Epub 2023 Jul 24.

Abstract

Growth differentiation factor 15 (GDF15) is believed to be a major causative factor for cancer-induced cachexia. Recent elucidation of the central circuits involved in GDF15 function and its signaling through the glial cell-derived neurotrophic factor family receptor α-like (GFRAL) has prompted the interest of targeting the GDF15-GFRAL signaling for energy homeostasis and body weight regulation. Here, we applied advanced peptide technologies to identify GDF15 peptide fragments inhibiting GFRAL signaling. SPOT peptide arrays revealed binding of GDF15 C-terminal peptide fragments to the extracellular domain of GFRAL. Parallel solid-phase peptide synthesis allowed for generation of complementary GDF15 peptide libraries and their subsequent functional evaluation in cells expressing the GFRAL/RET receptor complex. We identified a series of C-terminal fragments of GDF15 inhibiting GFRAL activity in the micromolar range. These novel GFRAL peptide inhibitors could serve as valuable tools for further development of peptide therapeutics towards the treatment of cachexia and other wasting disorders.

Keywords: Cachexia; GDF15; GFRAL; Peptide inhibitors; Peptide technologies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Body Weight / physiology
  • Cachexia* / metabolism
  • Growth Differentiation Factor 15 / metabolism
  • Growth Differentiation Factor 15 / pharmacology
  • Humans
  • Obesity* / metabolism
  • Peptide Fragments / pharmacology

Substances

  • Growth Differentiation Factor 15
  • Peptide Fragments
  • GDF15 protein, human